Cortisol And Reproductive Hormones Research

---

Table of Contents

1. Introduction: Why the Stress–Reproduction Connection Matters
2. The HPA and HPG Axes: An Integrated Overview
3. How Cortisol Suppresses the Reproductive Cascade
4. Cortisol and Estrogen: What the Research Reveals
5. Cortisol and Progesterone: Cycle Timing, Luteal Phase, and Beyond
6. Cortisol and Testosterone: Evidence Across Sexes
7. The HPA Reproductive Axis in Context: Acute vs. Chronic Stress
8. Cortisol Fertility Research: Male and Female Infertility Data
9. Cortisol Sex Hormones in Special Populations
10. Biomarker Methods: Serum, Saliva, and Urine Cortisol in Reproductive Studies
11. Clinical and Therapeutic Implications
12. Summary and Research Gaps
13. Frequently Asked Questions

---

Introduction: Why the Stress–Reproduction Connection Matters

Few areas of endocrinology carry as much clinical weight as the interplay between the stress response and reproductive function. The idea that psychological or physiological stress can impair fertility is not a modern folk belief — it is a mechanistically grounded reality with an expanding evidence base. Research into cortisol and reproductive hormones has accelerated markedly over the past two decades, driven by rising rates of infertility, better hormonal assay technology, and a growing appreciation of how systems-level crosstalk shapes clinical outcomes.

Cortisol, the primary glucocorticoid secreted by the adrenal cortex in response to hypothalamic-pituitary-adrenal (HPA) axis activation, is far more than a "stress hormone." It is a master regulator of metabolism, immunity, and — as contemporary research increasingly confirms — the reproductive endocrine system. When cortisol levels are acutely elevated, the body appropriately deprioritises reproduction. When elevation becomes chronic, however, the downstream consequences for fertility, cycle regularity, and gonadal steroidogenesis can be profound and difficult to reverse without targeted intervention.

This post synthesises the most current literature on cortisol reproductive hormones research, incorporating data from 2023 through 2026, examining mechanisms at the molecular, neuroendocrine, and clinical levels. Whether you are a reproductive endocrinologist, a researcher designing a clinical trial, or a clinician counselling patients with unexplained infertility, the evidence reviewed here offers a rigorous and practical framework.

---

The HPA and HPG Axes: An Integrated Overview

Two Axes, One Integrated System

To understand the science, it is essential to appreciate the architecture of the two principal endocrine systems at play.

The hypothalamic-pituitary-adrenal (HPA) axis governs the stress response. The hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which in turn drives adrenocortical secretion of cortisol. Cortisol then exerts negative feedback at both the hypothalamic and pituitary levels to restrain further HPA activation — a system designed for precision and self-limitation.

The hypothalamic-pituitary-gonadal (HPG) axis governs reproduction. Gonadotropin-releasing hormone (GnRH) from the hypothalamus drives pulsatile release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary, which subsequently regulate gonadal synthesis of estrogen, progesterone, testosterone, and other sex steroids.

The HPA HPG axis interaction is not incidental — these two axes share anatomical proximity, receptor substrates, and feedback loops. CRH neurons in the paraventricular nucleus of the hypothalamus are immediately adjacent to GnRH-secreting neurons, and glucocorticoid receptors (GRs) are expressed throughout the HPG axis, including in GnRH neurons, gonadotrophs, and gonadal cells. This architecture means that cortisol, the principal HPA effector, has access to multiple interference points along the reproductive cascade.

Kisspeptin: The Critical Upstream Node

One of the most significant advances in understanding HPA reproductive axis interactions has been the identification of kisspeptin neurons as primary targets of glucocorticoid inhibition. Kisspeptin, a neuropeptide encoded by the KISS1 gene and its receptor KISS1R, serves as the upstream gatekeeper of GnRH pulsatility. A 2026 review published in Neuroendocrinology summarised animal-model evidence demonstrating that glucocorticoids suppress kisspeptin neurons, downstream GnRH secretion, gonadotropin release, and gonadal steroidogenesis in a coordinated, multi-level fashion. This represents a comprehensive architecture of reproductive suppression — not a simple single-point inhibition.

Understanding the HPA HPG axis as a bidirectional, multi-node system is foundational to interpreting the clinical data reviewed in subsequent sections.

---

How Cortisol Suppresses the Reproductive Cascade

Molecular Mechanisms of Reproductive Cortisol Mechanism

The reproductive cortisol mechanism operates at every level of the HPG axis:

1. Hypothalamic suppression via kisspeptin and GnRH

Glucocorticoids bind to GRs expressed on kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus. GR activation inhibits KISS1 transcription, reducing kisspeptin output. Because kisspeptin is obligatory for GnRH pulse generation, even modest reductions in kisspeptin tone translate into reduced GnRH pulsatility, pulse amplitude, and frequency. Cortisol also acts directly on GnRH neurons, which express GRs, further attenuating pulsatile GnRH release independent of kisspeptin.

2. Pituitary-level suppression of gonadotropins

At the pituitary, glucocorticoids reduce the sensitivity of gonadotrophs to GnRH stimulation and suppress LH and FSH synthesis and secretion directly. A landmark 2005 study published in Endocrine quantified this effect with remarkable precision: exogenous cortisol administration suppressed LH pulse frequency by up to 35%, delayed the follicular-phase estradiol rise by as much as 20 hours, and delayed or completely blocked the preovulatory LH and FSH surges. These are not trivial perturbations — a 20-hour delay in the estradiol rise, or a blocked LH surge, has direct consequences for ovulation timing and probability.

3. Gonadal-level suppression of steroidogenesis

Even when gonadotropin signals arrive at the gonads, elevated cortisol can blunt the steroidogenic response. In the ovary, cortisol inhibits granulosa cell aromatase activity (reducing estradiol synthesis) and luteal cell progesterone synthesis. In the testis, cortisol reduces Leydig cell testosterone output by suppressing steroidogenic acute regulatory (StAR) protein expression and 3β-hydroxysteroid dehydrogenase (3β-HSD) activity, two enzymes critical for testosterone biosynthesis.

4. CRH direct gonadal effects

CRH itself — released in parallel with, and upstream of, cortisol — has direct inhibitory effects on gonadal function. CRH receptors have been identified in granulosa cells and Leydig cells, and CRH can inhibit steroidogenesis independently of cortisol, adding a parallel suppressive pathway.

This multi-level reproductive cortisol mechanism explains why stress-associated reproductive dysfunction can be so difficult to attribute to any single hormonal change — the suppression is distributed across the entire axis simultaneously.

---

Cortisol and Estrogen: What the Research Reveals

The Follicular Phase Vulnerability Window

Cortisol estrogen research has centred particularly on the follicular phase of the menstrual cycle, when rising estradiol is required to trigger the preovulatory LH surge. As noted above, the 2005 Endocrine study demonstrated that cortisol can delay the follicular-phase estradiol rise by up to 20 hours — a finding with direct clinical relevance for cycle monitoring, intrauterine insemination timing, and in vitro fertilisation protocols.

The mechanism involves cortisol-mediated suppression of aromatase (CYP19A1) in granulosa cells. Aromatase converts androgens (principally androstenedione and testosterone) to estrogens (estrone and estradiol). When cortisol inhibits aromatase expression, intrafollicular androgen accumulation may result alongside estradiol deficiency — a hormonal environment that can impair oocyte maturation and follicular development.

Estrogen-Cortisol Bidirectionality

The relationship is not unidirectional. Estradiol, particularly at higher concentrations, appears to modulate HPA axis reactivity. Estradiol has been shown to increase CRH gene expression in some hypothalamic regions while simultaneously enhancing negative feedback sensitivity at the pituitary level, producing a net effect that varies across the menstrual cycle. This bidirectionality — where estrogen shapes HPA reactivity and cortisol shapes estrogen production — creates a dynamic feedback loop that is highly cycle-phase dependent. Researchers studying cortisol estrogen research must therefore account carefully for cycle phase in study design.

PCOS as a Study Model

Polycystic ovary syndrome (PCOS) offers a particularly informative model for cortisol-estrogen interactions. A 2024 prospective study examined serum vitamin D and salivary cortisol as modulators of endocrine dysregulation in women with PCOS, highlighting how chronic low-grade HPA activation may contribute to the hormonal milieu characteristic of the condition. Women with PCOS already exhibit relative hyperandrogenism and impaired aromatase activity; if elevated cortisol further suppresses aromatase, the resulting androgen-to-estrogen ratio may exacerbate both metabolic and reproductive features of the syndrome.

---

Cortisol and Progesterone: Cycle Timing, Luteal Phase, and Beyond

Structural Homology and Receptor Competition

Cortisol progesterone interactions begin at the molecular level: cortisol and progesterone are structurally similar steroid hormones that share partial affinity for each other's receptors. Progesterone can bind the glucocorticoid receptor (GR) with low affinity, and cortisol can bind the progesterone receptor (PR) — though these cross-receptor interactions are typically considered pharmacologically relevant only at supraphysiologic concentrations.

More clinically significant is the upstream competition for the shared precursor pregnenolone. Under conditions of sustained cortisol demand (such as chronic stress), the adrenal cortex preferentially channels pregnenolone toward cortisol synthesis. This may reduce the substrate available for progesterone synthesis — a phenomenon colloquially referred to as "cortisol steal" or "pregnenolone steal," though the mechanistic evidence for this effect being clinically meaningful in vivo remains an area of ongoing research.

Luteal Phase Insufficiency

The luteal phase is the post-ovulatory period during which the corpus luteum secretes progesterone to prepare the endometrium for potential embryo implantation. Luteal phase insufficiency (LPI) — characterised by inadequate or abbreviated progesterone secretion — has been associated with recurrent early pregnancy loss and implantation failure.

Research into cortisol progesterone dynamics suggests that HPA axis activation during the luteal phase may accelerate cortisol-mediated luteolysis and reduce luteal cell progesterone output. The blocked or delayed LH surge documented in the 2005 Endocrine study has downstream consequences not only for ovulation but for corpus luteum quality: a suboptimal LH surge may produce a corpus luteum with reduced steroidogenic capacity, translating into lower progesterone levels during the luteal phase.

Can Stress Lower Progesterone?

This is one of the most frequently asked questions in reproductive endocrinology consultations. The evidence suggests: yes, through multiple mechanisms. Cortisol can suppress LH (which maintains the corpus luteum), inhibit luteal cell steroidogenesis directly, and potentially compete for pregnenolone substrate. However, the clinical magnitude of these effects is likely highly variable and dependent on the timing, duration, and intensity of cortisol elevation relative to cycle phase.

---

Cortisol and Testosterone: Evidence Across Sexes

Male Testosterone Suppression

Cortisol testosterone research has yielded some of the most consistent findings in reproductive endocrinology. In men, the testicular Leydig cells are the primary site of testosterone synthesis, and GRs are abundantly expressed in these cells. Glucocorticoid binding to testicular GRs suppresses StAR protein — which facilitates cholesterol transport into the inner mitochondrial membrane, the rate-limiting step in steroidogenesis — as well as multiple downstream steroidogenic enzymes.

Acute psychological stressors have been shown to produce transient testosterone decrements in men, while chronic stress-related cortisol elevation is associated with more sustained hypoandrogenaemia. The magnitude of testosterone suppression correlates with the degree of HPA axis hyperactivation in several clinical populations, including men with major depression, military personnel during intense training, and men with poorly controlled adrenal disorders.

Postmenopausal Women: A Paradoxical Positive Correlation

A particularly intriguing finding emerged from a 2026 retrospective study examining severity-dependent HPG-axis changes. In postmenopausal women, serum cortisol showed a negative correlation with FSH (P = 0.014) and LH (P = 0.016) but a positive correlation with testosterone (P < 0.001). This positive cortisol-testosterone association in postmenopausal women appears paradoxical given the suppressive effects of cortisol on testosterone seen in men and premenopausal women.

The likely explanation relates to the hormonal context of postmenopause. In premenopausal women, ovarian testosterone production is regulated by LH, and cortisol-mediated LH suppression would reduce ovarian androgen output. In postmenopausal women, ovarian sex steroid production is largely quiescent, and the adrenal cortex becomes a proportionally more important source of androgens (via dehydroepiandrosterone sulfate [DHEA-S] and androstenedione conversion). Adrenal androgen production, driven partly by ACTH — which rises in concert with cortisol under HPA stimulation — may thus increase in parallel with cortisol in postmenopausal women, producing a positive rather than negative correlation.

This finding underscores the importance of reproductive context when interpreting cortisol testosterone relationships. The direction of the association is not fixed — it depends critically on the hormonal milieu, age, menopausal status, and the source of androgen being measured.

Women With PCOS

In women with PCOS, the cortisol-testosterone relationship is further complicated by adrenal androgen excess, which contributes to hyperandrogenism in a significant subset. Elevated cortisol — whether causally elevated or reactive — may amplify adrenal androgen output in these women, worsening the androgenic features of PCOS while simultaneously suppressing ovarian function through the HPG-level mechanisms described above.

---

The HPA Reproductive Axis in Context: Acute vs. Chronic Stress

Why the Distinction Matters Clinically

The HPA reproductive axis operates differently under acute versus chronic stress conditions, and this distinction is clinically and mechanistically important.

Acute stress produces a rapid, transient cortisol spike that activates the "fight-or-flight" response. The reproductive suppression induced by acute cortisol elevation is typically short-lived and reversible. In the context of the ovarian cycle, an acute stress event timed badly — for example, immediately before the expected LH surge — could theoretically delay or blunt the surge, as documented in the 2005 Endocrine study. However, once cortisol normalises and the HPA axis returns to baseline, reproductive function generally recovers.

Chronic stress produces sustained HPA axis hyperactivation with persistently elevated cortisol. This changes the biology fundamentally: glucocorticoid receptor downregulation and altered sensitivity, hypothalamic CRH hypersecretion, altered GnRH pulsatility patterns, and progressive deterioration of luteal function can all develop over time. The 2026 biomarker-based study published in PubMed documented this precisely — elevated cortisol and disruptions in reproductive hormones were observed in individuals with high chronic stress, alongside disruptions in thyroid hormones. This systemic endocrine perturbation represents a chronic disease state rather than a transient physiological adaptation.

HPA Axis Dysregulation Patterns

Chronic stress does not always produce uniformly elevated cortisol. HPA axis dysregulation can manifest as:

• Hypercortisolism (elevated baseline and/or peak cortisol) — most commonly associated with reproductive suppression
• Blunted cortisol awakening response — seen in burnout and chronic fatigue states, associated with altered GnRH pulsatility
• Flattened diurnal cortisol profile — loss of the normal morning peak and evening nadir, which disrupts the temporal relationship between cortisol and reproductive hormone pulses
• Exaggerated cortisol reactivity — with normal baseline but excessive response to stressors, potentially disrupting cycle-phase-specific hormonal events

Research designs that measure cortisol only once (e.g., a single morning serum sample) may miss these dysregulation patterns. This has implications for interpreting inconsistent findings in the HPA reproductive literature, discussed further in the biomarker section below.

---

Cortisol Fertility Research: Male and Female Infertility Data

Systematic Review Landscape

Cortisol fertility research has grown substantially in both volume and methodological quality over the past decade, though the literature remains characterised by heterogeneity. A 2023 systematic review published in Frontiers in Endocrinology examined the association between cortisol and infertility across male and female studies:

• Among male infertility studies: 3 studies reported elevated cortisol in infertile men, while 1 study found no difference compared to controls.
• Among female infertility studies: 4 studies reported elevated cortisol in infertile women, while 3 found no difference.

This mixed landscape does not indicate that cortisol is unimportant — rather, it reflects the methodological challenges inherent in this research area: heterogeneous patient populations, varying definitions of "infertility," single time-point cortisol measurements, failure to control for cycle phase, and the absence of standardised cut-offs for defining "elevated" cortisol.

Male Fertility: Sperm Parameters and Cortisol

In men, cortisol-associated infertility research has focused particularly on sperm parameters — concentration, motility, morphology, and total sperm count. Leydig cell testosterone suppression by cortisol is relevant here, since testosterone is obligatory for spermatogenesis. However, cortisol may also have direct effects on Sertoli cells (which support germ cell development) and on the blood-testis barrier integrity.

The most compelling recent data on cortisol-mediated male infertility comes not from observational studies but from interventional research in a defined population: men with congenital adrenal hyperplasia (CAH). This is addressed in detail in the special populations section below.

Female Fertility: Ovulation, Implantation, and Pregnancy Rates

In women undergoing assisted reproductive technology (ART), the relationship between stress biomarkers and treatment outcomes has been studied extensively, though with inconsistent results. Some studies report that elevated cortisol or self-reported stress at the time of embryo transfer is associated with reduced clinical pregnancy rates, while others find no significant association. The heterogeneity likely reflects differences in ART protocols, embryo quality variables, and the timing and method of cortisol measurement.

More consistent findings emerge from studies of anovulation and cycle irregularity. Women with hypothalamic amenorrhoea — a clinical syndrome driven substantially by HPA hyperactivation — demonstrate markedly suppressed GnRH pulsatility and gonadotropin secretion, with cortisol elevation as a consistent biomarker. This represents the most severe end of the cortisol-fertility spectrum.

---

Cortisol Sex Hormones in Special Populations

Congenital Adrenal Hyperplasia: A Natural Experiment

Congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deficiency, provides a uniquely informative lens on cortisol sex hormones interactions. In CAH, impaired cortisol synthesis leads to loss of HPA negative feedback, ACTH hypersecretion, adrenal hyperplasia, and excess adrenal androgen production. This hormonal environment creates profound reproductive dysfunction in both sexes: oligospermia and testicular adrenal rest tumours (TARTs) in men, and menstrual irregularity, anovulation, and hyperandrogenism in women.

The 2024–2025 CALLIOPE multicenter prospective study examined adult men with CAH treated with modified-release hydrocortisone (MR-HC), a formulation designed to mimic the physiological circadian cortisol profile more closely than conventional immediate-release hydrocortisone. After approximately 5.7 months of MR-HC treatment, sperm concentration increased by 72.3% and total sperm count by 71.84%. These are remarkable improvements in a population where subfertility is nearly universal without treatment. The findings suggest that restoring physiological cortisol exposure — particularly the diurnal pattern — is sufficient to substantially recover spermatogenic function, demonstrating the profound fertility consequences of cortisol dysregulation and the therapeutic potential of its correction.

Postmenopausal Women: Revisiting the Cortisol-FSH-LH-Testosterone Pattern

As described above, the 2026 retrospective study found that in postmenopausal women, cortisol correlated negatively with FSH (P = 0.014) and LH (P = 0.016) while correlating positively with testosterone (P < 0.001). This patterning — HPA-driven suppression of pituitary gonadotropins alongside HPA-driven adrenal androgen elevation — has implications for the assessment and management of postmenopausal women presenting with symptoms of hyperandrogenism or unexplained gonadotropin suppression. Cortisol measurement may be informative in this population even in the absence of overt adrenal pathology.

PCOS: Overlapping HPA and HPG Dysregulation

Women with PCOS demonstrate several features of HPA axis dysregulation alongside HPG axis abnormalities. Salivary cortisol profiles in PCOS women have shown altered diurnal rhythms and exaggerated stress reactivity in some — though not all — studies. The 2024 study examining salivary cortisol and serum vitamin D in PCOS adds to evidence that adrenal androgen excess in PCOS may be partially driven by HPA hyperactivation. This has therapeutic implications: if cortisol dysregulation is contributing to adrenal androgen excess in PCOS, interventions targeting HPA axis regulation (including sleep optimisation, stress reduction, and potentially low-dose glucocorticoid therapy in specific cases) might complement standard PCOS management.

Athletes and Hypothalamic Amenorrhoea

Female athletes under conditions of relative energy deficiency (previously termed "female athlete triad") represent another well-characterised population where cortisol sex hormones dysregulation is clinically prominent. Exercise-associated energy deficiency activates the HPA axis, elevating CRH and cortisol, while simultaneously suppressing kisspeptin and GnRH pulsatility. The result is functional hypothalamic amenorrhoea — anovulation, oestrogen deficiency, and impaired bone mineralisation. This population illustrates how the cortisol-reproductive hormone axis responds to metabolic as well as psychological stress signals, consistent with the evolutionary logic of reproductive suppression under resource-scarcity conditions.

---

Biomarker Methods: Serum, Saliva, and Urine Cortisol in Reproductive Studies

Are All Cortisol Measurement Methods Equally Useful?

One of the most practically important questions in cortisol fertility research and endocrinology more broadly is whether serum, salivary, and urinary cortisol measurements are interchangeable, and which is most appropriate for different research or clinical questions.

Serum cortisol measures total cortisol (bound plus free), with approximately 90–95% bound to corticosteroid-binding globulin (CBG) and albumin. Only free cortisol is biologically active. Serum cortisol is influenced by CBG levels, which change with oestrogen exposure (rising substantially in pregnancy and with oestrogen-containing contraceptives), meaning that comparisons of serum cortisol across hormonal contexts require careful interpretation. Serum cortisol is the most commonly used measure in clinical endocrinology, but a single morning measurement captures only a snapshot of a highly dynamic system.

Salivary cortisol measures free cortisol specifically (unbound, biologically active fraction), is non-invasive, and can be collected at multiple time points across the day to characterise the diurnal profile — including the cortisol awakening response (CAR), which has particular relevance for HPA axis function assessment. Salivary cortisol is increasingly preferred in stress and reproductive research for these reasons, and the 2024 PCOS study explicitly used salivary cortisol to capture free cortisol dynamics in that population.

Urinary free cortisol (24-hour collection) provides an integrated measure of daily free cortisol production, unaffected by the episodic pulsatility that can make single time-point measurements unreliable. It is the gold standard for diagnosing hypercortisolism (Cushing's syndrome) and provides a more stable reflection of chronic cortisol exposure — relevant when examining chronic stress and reproductive outcome associations.

Hair cortisol is an emerging measure that captures cortisol accumulated in hair over weeks to months, providing a retrospective window into long-term HPA activity. Though not yet standard in reproductive endocrinology research, hair cortisol has been used in fertility studies to assess chronic stress exposure preceding ART cycles.

Methodological Implications for Interpreting the Literature

The inconsistency across cortisol fertility research studies — particularly the mixed findings of the 2023 systematic review — is substantially attributable to measurement heterogeneity. Studies using single-timepoint serum cortisol are likely to miss patterns of HPA dysregulation that manifest primarily as altered diurnal rhythm, exaggerated reactivity, or a blunted CAR. Future research in this field would benefit substantially from:

• Multi-timepoint salivary cortisol sampling (at minimum awakening, 30 minutes post-awakening, and evening)
• Cycle-phase-controlled timing of hormonal measurements in women
• Concurrent measurement of CBG when interpreting serum cortisol in oestrogen-exposed subjects
• Integration of urinary and hair cortisol where long-term HPA activity is the exposure of interest

---

Clinical and Therapeutic Implications

What Does This Mean for Practice?

The evidence reviewed here has several practical clinical implications:

1. HPA assessment as part of infertility workup

While routine cortisol testing is not currently standard in infertility assessment, the evidence suggests it may be informative in specific clinical scenarios: women with hypothalamic amenorrhoea, oligomenorrhoea, or luteal phase deficiency; men with unexplained oligospermia; and patients with a history of significant chronic stress, adrenal pathology, or glucocorticoid use. A multi-timepoint salivary cortisol profile is likely more informative than a single morning serum sample in these contexts.

2. Cortisol-targeted treatment in adrenal disorders

The CALLIOPE study data on modified-release hydrocortisone in CAH men provides compelling evidence that physiological cortisol replacement — specifically, restoration of a normal circadian cortisol profile — can dramatically improve spermatogenic function. The 72.3% increase in sperm concentration after approximately 5.7 months of treatment represents a clinically meaningful intervention that should inform standard of care for men with CAH seeking fertility.

3. Stress management as adjunctive fertility care

For patients with chronic stress-associated HPA dysregulation and reproductive consequences, evidence-based stress management interventions — cognitive-behavioural therapy, mindfulness-based stress reduction, and structured exercise within energy-balanced parameters — have demonstrated HPA axis normalisation effects in randomised controlled trials. The downstream reproductive benefits of these interventions are plausible given the mechanistic evidence, though large-scale fertility-outcome trials remain limited.

4. Timing sensitivity in ART cycles

The finding that cortisol can delay the follicular-phase estradiol rise by up to 20 hours has direct implications for cycle monitoring in natural and stimulated ART cycles. Clinicians should be alert to the possibility that acute stress-related cortisol elevation may alter the timing of hormonal events, potentially affecting trigger timing decisions in IVF protocols.

5. PCOS management considerations

Evidence of HPA-driven adrenal androgen excess in a subset of PCOS women suggests that adrenal function assessment — including cortisol and DHEA-S measurements — should be part of the comprehensive hormonal evaluation of PCOS. Low-dose dexamethasone or physiological glucocorticoid therapy has been used adjunctively in PCOS women with demonstrable adrenal hyperandrogenism, though this approach requires careful benefit-risk assessment.

---

Summary and Research Gaps

What We Know With Confidence

The evidence base for cortisol and reproductive hormones research now supports several mechanistically and clinically robust conclusions:

1. Multi-level suppression is real and quantifiable. Cortisol suppresses the reproductive axis at the hypothalamic (kisspeptin, GnRH), pituitary (LH, FSH), and gonadal (estrogen, progesterone, testosterone) levels simultaneously. The 2026 Neuroendocrinology review of animal models and the 2005 Endocrine clinical study both provide strong quantitative support for this.

1. The HPA HPG axis interaction is context-dependent. The direction and magnitude of cortisol-sex hormone associations vary with sex, reproductive stage, menopausal status, and the type and chronicity of HPA activation. The paradoxical positive cortisol-testosterone correlation in postmenopausal women from the 2026 retrospective study illustrates this context-dependence clearly.

1. Chronic stress produces multi-system endocrine disruption. The 2026 biomarker-based study documents elevated cortisol alongside disruptions in both reproductive and thyroid hormones in high-stress individuals, situating reproductive dysfunction within a broader context of systemic endocrine perturbation.

1. Physiological cortisol restoration can recover reproductive function. The CALLIOPE study's 72%+ improvements in sperm parameters after MR-HC in CAH men provides the strongest interventional evidence to date that the cortisol-reproductive hormone relationship is not merely associative but causally important and therapeutically modifiable.

1. The systematic review evidence is mixed but directionally consistent. The 2023 Frontiers systematic review found elevated cortisol in the majority of both male and female infertility studies reviewed, despite some negative findings — consistent with a real but heterogeneous association.

Key Research Gaps

Despite significant progress, important gaps remain:

• Longitudinal studies tracking HPA and HPG dynamics simultaneously across full menstrual cycles in reproductive-age women with infertility are sparse. Most studies are cross-sectional.
• Dose-response relationships between cortisol elevation magnitude/duration and reproductive outcome impairment are incompletely characterised.
• Interventional trials targeting HPA normalisation as a primary fertility intervention (rather than stress management as an adjunct) are lacking.
• Sex-specific mechanisms beyond the well-studied male testosterone pathway — particularly cortisol effects on female folliculogenesis, oocyte competence, and endometrial receptivity — need further investigation.
• Biomarker standardisation across cortisol measurement methods, timing, and reference ranges remains a barrier to meta-analytic synthesis.
• Translational validation of the robust animal-model kisspeptin suppression data in human subjects is incomplete.

---

Frequently Asked Questions

Does high cortisol affect ovulation?

Yes — through multiple mechanisms. Elevated cortisol suppresses GnRH pulsatility (via kisspeptin inhibition), reduces LH pulse frequency (by up to 35% in clinical studies), delays the follicular-phase estradiol rise (by up to 20 hours), and can delay or completely block the preovulatory LH and FSH surges. Any of these effects, individually or in combination, can disrupt or prevent ovulation. The impact depends on the timing and magnitude of cortisol elevation relative to cycle phase.

Can stress lower progesterone, LH, or FSH?

Yes to all three, through the mechanisms described above. LH suppression is the most directly documented effect of cortisol in clinical studies. FSH is also suppressed, though typically less acutely than LH. Progesterone suppression occurs secondarily — either through impaired LH-driven luteal support, direct inhibition of luteal steroidogenesis, or potential competition for pregnenolone substrate.

Is cortisol linked to infertility in men and women?

The 2023 systematic review found that the majority of male and female infertility studies reported elevated cortisol in the affected groups, though a minority found no difference. The association is most convincingly demonstrated in specific populations — men with CAH, women with hypothalamic amenorrhoea, and individuals with documented chronic stress — rather than across the full spectrum of "unexplained infertility." Mechanistically, the link is well-supported; clinically, the evidence base is growing but not yet definitive across all infertility presentations.

Can cortisol changes affect testosterone or menstrual cycle timing?

Yes on both counts. Cortisol suppresses testosterone in men via Leydig cell inhibition, and in premenopausal women via LH-mediated ovarian androgen reduction. The direction may reverse in postmenopausal women, as shown by the 2026 study. Menstrual cycle timing can be disrupted through cortisol-mediated delays in the estradiol rise, altered LH surge timing, or impaired luteal function, all of which can produce cycle lengthening, irregularity, or anovulation.

What is the difference between acute stress effects and chronic cortisol elevation?

Acute stress produces transient, reversible cortisol elevation with short-lived reproductive suppression. If timed around critical cycle events (like the preovulatory LH surge), even acute elevation may have consequences, but normal function resumes when cortisol normalises. Chronic cortisol elevation produces sustained axis suppression with GR downregulation, progressive alterations in GnRH pulsatility, luteal insufficiency, and potentially longer-lasting reproductive impairment that may not self-correct without addressing the underlying HPA dysregulation.

Are saliva, serum, and urinary cortisol tests equally useful for reproductive hormone research?

No — each captures different aspects of cortisol physiology. Serum cortisol measures total cortisol (mostly bound) and is affected by CBG levels, which change with oestrogen. Salivary cortisol measures free (bioactive) cortisol and allows multi-timepoint diurnal profiling. Urinary free cortisol integrates daily free cortisol production. For reproductive research, multi-timepoint salivary cortisol sampling is generally preferred because it captures the biologically active fraction and the diurnal dynamics relevant to GnRH pulsatility and reproductive hormone rhythms.

Can cortisol treatment improve reproductive outcomes in adrenal disorders?

Yes — the CALLIOPE study provides compelling evidence. Men with congenital adrenal hyperplasia treated with modified-release hydrocortisone (designed to mimic the physiological circadian cortisol profile) experienced a 72.3% increase in sperm concentration and a 71.84% increase in total sperm count after approximately 5.7 months of treatment. This suggests that normalising cortisol replacement therapy — restoring both adequate levels and a normal diurnal pattern — is a meaningful reproductive intervention in adrenal disorder populations.

---

This article is intended for educational and scientific purposes. It reflects published research literature as of mid-2026 and does not constitute medical advice. Clinical decisions regarding cortisol testing, interpretation, and treatment should be made in consultation with a qualified endocrinologist or reproductive medicine specialist.

---

References (Key Sources)

1. Frontiers in Endocrinology (2026). Severity-dependent HPG-axis changes and cortisol correlations in postmenopausal women. Front. Endocrinol. DOI: 10.3389/fendo.2026.1681387
2. PubMed (2026). Biomarker-based study on chronic stress, cortisol, and reproductive hormone disruption. PMID: 41960455
3. Frontiers in Endocrinology (2023). Systematic review of cortisol and infertility outcomes. Front. Endocrinol. DOI: 10.3389/fendo.2023.1147306
4. Neuroendocrinology (2026). Review of glucocorticoid suppression of kisspeptin, GnRH, and gonadotropins in animal models.
5. Endocrine (2005). Cortisol effects on LH pulse frequency, follicular-phase estradiol, and preovulatory surge timing.
6. Oxford University Press / CALLIOPE Study (2025). Modified-release hydrocortisone and sperm parameters in adult men with congenital adrenal hyperplasia.
7. Prospective PCOS study (2024). Salivary cortisol and serum vitamin D as modulators of endocrine dysregulation in PCOS women.